Clinical Trial Update: Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2a study of IPG7236 in patients with solid tumors is currently recruiting. The trial will assess safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• IPG7236

Snippet

Sponsor: Nanjing Immunophage Biotech Co., Ltd | Conditions: Safety Issues, Tolerability | Phase 1, Phase 2 | Status: RECRUITING